Biotech Values

[mcbio]

QURE - Baxter was a previously partner with Chatham Therapeutics on their Hemophilia treatments and had previously paid $25 million to Chatham related to the development of those treatments. I assume their relationship was a driving factor to the eventual purchase.

Took a closer look at QURE's pipeline (http://www.uniqure.com/pipeline/clinical-pipeline/ ) and they seem to have a lot more going on than just the hemophilia program. What do you make of the opportunity for the lead drug Glybera? It's apparently already approved in the EU under "exceptional circumstances" and it appears they are looking to broaden approval in EU and ultimately the U.S. Lipoprotein lipase deficiency is an orphan disease and unmet need according to the company. Then there are programs for Acute Intermittent Porphyria, Sanfilippo B Syndrome, and also Parkinson's. Seems like they have a lot going on.